On 22 November 2017, the European Medicines Agency (EMA) will launch a new and improved version of EudraVigilance, the European information system of suspected adverse reactions to medicines that are authorised or being studied in clinical trials in the European Economic Area (EEA). The new system will have enhanced features for the reporting and analysis of suspected adverse reactions to support a better safety monitoring of medicines and a more efficient reporting process for stakeholders.
Some functionalities of the system will be entirely or partially unavailable for a period of ten working days, from 08 to 21 November 2017.
The planned EudraVigilance downtime period will not affect the direct reporting of side effects by patients and healthcare professionals to national authorities in the European Union (EU) Member States or to marketing authorisation holders (MAHs).
Alternative reporting arrangements are being put in place to ensure that important processes can continue during the downtime. These include in the particular established process for MAHs and sponsors of clinical trials to notify any emerging safety issues immediately to EU Member States and EMA.